國家衛生研究院 NHRI:Item 3990099045/14166
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12441/13613 (91%)
造访人次 : 2385863      在线人数 : 172
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14166


    题名: Pioglitazone and prostate cancer risk in Taiwanese male patients with type 2 diabetes: A retrospective cohort study
    作者: Tseng, CH
    贡献者: National Institute of Environmental Health Sciences
    摘要: Purpose: This study investigated prostate cancer risk associated with pioglitazone use. Materials and Methods: The Taiwan's National Health Insurance database was used to create a propensity score-matched cohort of male patients with type 2 diabetes mellitus newly diagnosed in 1999-2005 and aged >= 25 years at baseline. The matched cohort included 20437 ever users and 20437 never users of pioglitazone. The patients were followed up for the incidence of prostate cancer until December 31, 2011. Hazard ratios (HRs) were created from Cox regression weighted on propensity score. Results: Prostate cancer was diagnosed in 121 ever users of pioglitazone (incidence: 175.84 per 100,000 person-years) and 143 never users of pioglitazone (incidence: 216.66 per 100,000 person-years). When ever users were compared to never users of pioglitazone, the HR was 0.815 (95% confidence interval [CI], 0.639-1.039; p=0.0987). When ever users were categorized into tertiles of cumulative duration of pioglitazone therapy ( 6.83, 6.83-20.23, and 5,040, 5,040-15,330, and 65 years (HR, 0.578; 95% CI, 0.360-0.927) but not in patients aged >= 65 years. Conclusions: A significantly lower risk of prostate cancer is observed after a cumulative duration of pioglitazone therapy for 20.23 months or a cumulative dose of >15,330 mg. The risk reduction is mainly observed in patients aged <65 years.
    日期: 2023-01
    關聯: World Journal of Mens Health. 2023 Jan;40:Article number e37.
    Link to: http://dx.doi.org/10.5534/wjmh.210157
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2287-4208&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000766646400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85127511989
    显示于类别:[其他] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000766646400001.pdf626KbAdobe PDF202检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈